bioAffinity Technologies Files 8-K on Financials
Ticker: BIAFW · Form: 8-K · Filed: May 16, 2024 · CIK: 1712762
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on May 15th detailing financial results. Check it out.
AI Summary
bioAffinity Technologies, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in San Antonio, Texas.
Why It Matters
This 8-K filing provides investors with crucial updates on bioAffinity Technologies' financial performance and condition, which can influence investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not inherently present new risks.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- May 15, 2024 (date) — Date of earliest event reported
- San Antonio, Texas (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of bioAffinity Technologies, Inc., and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 15, 2024.
Where are bioAffinity Technologies, Inc.'s principal executive offices located?
bioAffinity Technologies, Inc.'s principal executive offices are located at 22211 W Interstate 10 Suite 1206, San Antonio, Texas 78257.
What is the Commission File Number for bioAffinity Technologies, Inc.?
The Commission File Number for bioAffinity Technologies, Inc. is 001-41463.
What is the Standard Industrial Classification (SIC) code for bioAffinity Technologies, Inc.?
The Standard Industrial Classification (SIC) code for bioAffinity Technologies, Inc. is 8731, which falls under SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-15 18:07:52
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 73KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001493152-24-020059.txt ( ) — 346KB
- biaf-20240515.xsd (EX-101.SCH) — 4KB
- biaf-20240515_def.xml (EX-101.DEF) — 26KB
- biaf-20240515_lab.xml (EX-101.LAB) — 36KB
- biaf-20240515_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 15, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer